Back to mobile site

H.C. Wainwright Reiterates Buy Rating on Aquestive Therapeutics (AQST)

March 10, 2025 6:49 AM EDT Send to a Friend
H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $10.00 price target on Aquestive Therapeutics (NASDAQ: AQST).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login